Milestones

Following the philosophy of "Precise Products, Predictable Effects, Health Protection", Kexing Biopharm is devoted to promoting the R&D of quality biopharmaceutical products with improved clinical value, acting as the safeguard of human's health.

1989

Shenzhen Kexing Bioproducts Co., Ltd., was established as an industrial base for interferon production.
1996

"Human Interferon α1b for Injection" (SINOGEN) was officially approved for production as Class I biological products.
1997

Shandong Kexing Bioproducts Co., Ltd. was established as an industrial platform for recombinant human erythropoietin.
1998

"Human Erythropoietin Injection (CHO Cell)" (EPOSINO) was officially approved for production as Class II biological products.
2000

Shenzhen Sinovac was recognized by the Ministry of Science and Technology as the "Industrialization Base of National 863 Plan Achievement"
2001

"Human Granulocyte Colony-stimulating Factor Injection"(WHITE-C) was officially approved for production.
2002

Combined Clostridium Butyricum and Bifidobacterium Powder/Capsule, Live (CLOBICO) was officially approved for production.
2009

The EPO agent not containing albumin obtained the certificate of invention patent (patent No. ZL200610146206.0).
2014

We integrated the traditional Chinese medicine business focusing on KEHUANG CAPSULE around hepatopathy treatment.
2017

Our technology center was ratified as the "Shandong Provincial Enterprise-level Technology Center"
2018

Our technology center was ratified as the "Jinan Protein Therapeutics Engineering Laboratory".
2019

We launched the slogan "Precise Products, Predictable Effects, Health Protection" and the new logo.
2019

The company was restructured into Kexing Biopharmaceutical Co., Ltd. (Kexing Biopharm).
2020

Our technology center was ratified as the "Shandong Protein Therapeutics Engineering Laboratory".
2020

Our technology center was ratified as the "Guangdong Gene Engineering Recombinant Protein Therapeutics Engineering Technology Center".
2020

The company successfully landed on the A-share technology innovation board with the stock code of 688136, becoming the leader of high quality biologicals.
2020

The company was approved to set up the "Shenzhen postdoctoral innovation practice base".
2021

Kexing Biopharm signed a Drug Cooperation Agreement with Haichang Biotech to obtain the commercial license of HC007 (a complex preparation for injection, a generic drug of a broad-spectrum anticancer drug) in all regions except the US.